Top US gainer in pre-market deals was Xilinx Inc (NASDAQ:XLNX), which raced up over 9% to US$74.10.
The device firm reported better-than-expected quarterly results and issued an outlook for the current quarter, which exceeded analyst projections.
Revenue for the tech firm in the three months rose to US$684mln, up from US$603mln in the same period a year ago. Analysts had been projecting revenue of US$674mln.
Looking ahead, the group forecast revenue of between US$700mln and US$720mln in the second quarter, whereas analysts had been expecting US$680mln.
Elsewhere, Advanced Micro Devices Inc (NASDAQ:AMD), was also racing before the New York bell, with shares up 6.7% to US$17.14 after it proved analysts wrong with a strong set of Q2 numbers.
Revenue for the three months clocked in at US$1.76bn, which was an impressive 53% rise year-over-year, with gross margin up more than three percentage points, resulting in the chip company's highest quarterly net income in seven years.
Biogen Inc (NASDAQ:BIIB), the multi-national biotech, saw shares add 8.42% to US$351.50 after it unveiled second quarter profit, which breezed past analyst estimates.
Biogen earned US$5.80 per share versus analyst projections of US$5.21, while revenue rose 9% to stand at US$3.4bn, also topping Wall Street estimates.
Also cheering investors, an experimental drug from the company and its Japanese partner Eisai was shown to slow the decline in memory and thinking clearly associated with Alzheimer’s disease. Meanwhile, Qualcomm Inc (NASDAQ:QCOM) was another share riser before the bell, with the stock gaining over 6% to stand at US$63.05. Yesterday, shares added 0.97% to US$59.42.
The firm beat expectations with quarterly earnings, released after hours and it also revealed it was dropping its US$44bn deal to buy Dutch chipmaker NXP Semiconductors amid rising trade tensions between the U.S. and China.
Instead, Qualcomm will pay a US$2bn breakup fee to NXP and spend up to US$30 billion buying back its own shares, which cheered the market.